{"docstore/metadata": {"bf82a9c3-a399-4715-862b-a856a335e340": {"doc_hash": "7ad8fc2d95a00d5436f71283d1f2e51a3314e3fcce36fab12e76bdfc1243132e"}, "f3a19729-24d7-41e2-87f1-aee872bc1164": {"doc_hash": "5c43f6719fbc47cfb1d64519497ea94092034f435d0090a8fd37e6719600795e"}, "d1dd1697-b26c-4f3f-9b34-b255329be451": {"doc_hash": "148b182315bff0be8165c25a743539541ec798b264122fd6c36fdf80aaf3cfe4"}, "145f0a5a-0a41-4b87-ad16-b21180ee7a64": {"doc_hash": "9ed2d793f1589fc95b5073ce9b9cf0809f0b706334b2fc43d478a353b5aee150"}, "530d90bf-8d62-4be5-a0d1-00059b42ca38": {"doc_hash": "ef6de9249833668bd372bac20812243c2de976d0a9d204552c541085ead218b9"}, "01915641-fd0e-4fdd-9553-904b86b1af64": {"doc_hash": "5ef1f93e4314fedbb969fc8be89d8dd027f22285054dbb5241da470a7ae94e91"}, "d731f7c2-5373-4b52-b464-c3ee74af022f": {"doc_hash": "1038db7cd95a7ab0c2ae77f473ee80648f45dc40e0f76ccf5cb10b5b2ae1a7f1"}, "af630954-e6a2-4866-a665-ed379c83c154": {"doc_hash": "a0862c3bfa42732dbb946f8241bfd5fd1c6f0541160b8ef53f3922d2ccc18950"}, "9f892b52-a782-4048-bbb7-18eccfef09ba": {"doc_hash": "2e838eda0fa70c4cdf42baf5150bf09004220ab1a57c342df1ac7775f5aeed0a"}, "cd343e65-b67f-4b00-bd23-93f1e1bbe789": {"doc_hash": "9cda620e4213ee113fb3e7f9fadf73c23c5eb9c47d1602d60e00b36963e476b4"}, "ef6548f3-2f38-4a44-94e4-2f99ebf16d92": {"doc_hash": "2754ff9d32be124420bd5ada315136de2f74d51677afb83174eb4f3c2ecb35b6"}, "b4d06e64-f906-43bd-9fc7-5a82ce9759ea": {"doc_hash": "29951c9f023ace1bc83eae9f83fb89c8746c9c33521fd2dba980d4292e36a230", "ref_doc_id": "bf82a9c3-a399-4715-862b-a856a335e340"}, "c27672a9-cfa1-4432-9487-f48352c02b25": {"doc_hash": "c780093efa94d76703b00e3a38111e9a68f1609fa6c045a45a09a72b0259eb5f", "ref_doc_id": "f3a19729-24d7-41e2-87f1-aee872bc1164"}, "a93f0b95-36cf-4e90-a400-7dee8cd344fb": {"doc_hash": "89b4002afb8f8f3b80dc23810587f6e26aff3dfb1f9b33d52ef9c46b10efa80a", "ref_doc_id": "d1dd1697-b26c-4f3f-9b34-b255329be451"}, "1dfd9e77-f678-4134-8768-57f17c0c0a27": {"doc_hash": "2469e6f13aed57aa6d46fac561d995005f37641da5055c9733a6dc84f2e49bec", "ref_doc_id": "145f0a5a-0a41-4b87-ad16-b21180ee7a64"}, "005a9393-58a1-4999-bced-ffca970cb902": {"doc_hash": "31be4d5632eb921c35d54728d3387e1b21956476917a1ff32117a13e2bf82d8b", "ref_doc_id": "530d90bf-8d62-4be5-a0d1-00059b42ca38"}, "23b6c1de-1f91-4995-986a-ff751d206e42": {"doc_hash": "c764063eb4b97392c8b8ac3e67a092b5645bb48a1a29b78a2f7ccb78834abf8c", "ref_doc_id": "01915641-fd0e-4fdd-9553-904b86b1af64"}, "318628ba-cb78-44e5-806b-c2c4f344d7e7": {"doc_hash": "87789da111566c9dfc72300ff85511458057c269badc75f26b33dc83ca5d60f7", "ref_doc_id": "d731f7c2-5373-4b52-b464-c3ee74af022f"}, "ef15fda0-8df7-44a2-82eb-00127fab1094": {"doc_hash": "d3e98430a23b215310874c4436f16ad9fca89e2ba9d852fdb6874de631e9516a", "ref_doc_id": "af630954-e6a2-4866-a665-ed379c83c154"}, "7de2b2bb-0d24-470d-886a-4e75ae941eba": {"doc_hash": "84cab946454a4800db748559cfee0c91ec8ba24cc7befc578b9a65a5b808a84e", "ref_doc_id": "9f892b52-a782-4048-bbb7-18eccfef09ba"}, "ce1e3849-da68-404d-8117-65fec4e3dce9": {"doc_hash": "4ef4a51b4a940d9806a27c015689ff8abb5e09344499b743922df5efa5d427ce", "ref_doc_id": "cd343e65-b67f-4b00-bd23-93f1e1bbe789"}, "a4d5eb9f-a9ed-4ae5-8e03-9609edad5e5a": {"doc_hash": "2dd0568c7be549cf93caa2eb7ea635f5329d2e28314ba7ec262cd10a53ca46af", "ref_doc_id": "ef6548f3-2f38-4a44-94e4-2f99ebf16d92"}}, "docstore/ref_doc_info": {"bf82a9c3-a399-4715-862b-a856a335e340": {"node_ids": ["b4d06e64-f906-43bd-9fc7-5a82ce9759ea"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "f3a19729-24d7-41e2-87f1-aee872bc1164": {"node_ids": ["c27672a9-cfa1-4432-9487-f48352c02b25"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "d1dd1697-b26c-4f3f-9b34-b255329be451": {"node_ids": ["a93f0b95-36cf-4e90-a400-7dee8cd344fb"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "145f0a5a-0a41-4b87-ad16-b21180ee7a64": {"node_ids": ["1dfd9e77-f678-4134-8768-57f17c0c0a27"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "530d90bf-8d62-4be5-a0d1-00059b42ca38": {"node_ids": ["005a9393-58a1-4999-bced-ffca970cb902"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "01915641-fd0e-4fdd-9553-904b86b1af64": {"node_ids": ["23b6c1de-1f91-4995-986a-ff751d206e42"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "d731f7c2-5373-4b52-b464-c3ee74af022f": {"node_ids": ["318628ba-cb78-44e5-806b-c2c4f344d7e7"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "af630954-e6a2-4866-a665-ed379c83c154": {"node_ids": ["ef15fda0-8df7-44a2-82eb-00127fab1094"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "9f892b52-a782-4048-bbb7-18eccfef09ba": {"node_ids": ["7de2b2bb-0d24-470d-886a-4e75ae941eba"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "cd343e65-b67f-4b00-bd23-93f1e1bbe789": {"node_ids": ["ce1e3849-da68-404d-8117-65fec4e3dce9"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}, "ef6548f3-2f38-4a44-94e4-2f99ebf16d92": {"node_ids": ["a4d5eb9f-a9ed-4ae5-8e03-9609edad5e5a"], "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}}}, "docstore/data": {"b4d06e64-f906-43bd-9fc7-5a82ce9759ea": {"__data__": {"id_": "b4d06e64-f906-43bd-9fc7-5a82ce9759ea", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bf82a9c3-a399-4715-862b-a856a335e340", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "7ad8fc2d95a00d5436f71283d1f2e51a3314e3fcce36fab12e76bdfc1243132e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n- **Date of Birth:** 08/07/1995\n- **Patient Age:** 28\n- **Time of Collection:** Not Given\n- **Patient Sex:** Male\n- **Report Date:** 10/31/2023\n\n----\n\n**Metabolic Markers in Urine:**\n- **Reference Population:** Males Age 13 and Over\n- **Reference Range (mmol/mol creatinine)**\n\n**Intestinal Microbial Overgrowth:**\n\n**Yeast and Fungal Markers:**\n1. **Citramalic**:\n- Reference Range: 0.11 - 2.0\n- Patient Value: 0.66\n2. **5-Hydroxymethyl-2-furoic (Aspergillus)**:\n- Reference Range: \u2264 18\n- Patient Value: 14\n3. **3-Oxoglutaric**:\n- Reference Range: \u2264 0.11\n- Patient Value: 0.00\n4. **Furan-2,5-dicarboxylic (Aspergillus)**:\n- Reference Range: \u2264 13\n- Patient Value: 7.7\n5. **Furancarbonylglycine (Aspergillus)**:\n- Reference Range: \u2264 2.3\n- Patient Value: 0.00\n6. **Tartaric (Aspergillus)**:\n- Reference Range: \u2264 5.3\n- Patient Value: 0.20\n7. **Arabinose**:\n- Reference Range: \u2264 20\n- Patient Value: H 32\n8. **Carboxycitric**:\n- Reference Range: \u2264 20\n- Patient Value: 0.00\n9. **Tricarballylic (Fusarium)**:\n- Reference Range: \u2264 0.58\n- Patient Value: 0.13\n\n**Bacterial Markers:**\n10. **Hippuric**:\n- Reference Range: \u2264 241\n- Patient Value: 160\n11. **2-Hydroxyphenylacetic**:\n- Reference Range: 0.03 - 0.47\n- Patient Value: 0.41\n12. **4-Hydroxybenzoic**:\n- Reference Range: \u2264 0.73\n- Patient Value: 0.40\n13. **4-Hydroxyhippuric**:\n- Reference Range: \u2264 14\n- Patient Value: 2.6\n14. **DHPPA (Beneficial Bacteria)**:\n- Reference Range: \u2264 0.23\n- Patient Value: 0.06\n\n**Clostridia Bacterial Markers:**\n15. **4-Hydroxyphenylacetic**:\n- Reference Range: \u2264 18\n- Patient Value: 7.2\n16. **HPHPA**:\n- Reference Range: \u2264 102\n- Patient Value: 9.8\n17. **4-Cresol**:\n- Reference Range: \u2264 39\n- Patient Value: 3.5\n18. **3-Indoleacetic**:\n- Reference Range: \u2264 6.8\n- Patient Value: 0.55\n\n----\n\n**Disclaimer:**\nThis test was developed, and its performance characteristics determined by Mosaic Diagnostics Laboratory. It has not been cleared or approved by the US Food and Drug Administration.\n\n----\n\n**Document Title:** Organic Acids Test - Nutritional and Metabolic Profile\n**Page:** 1 of 11", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2234, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c27672a9-cfa1-4432-9487-f48352c02b25": {"__data__": {"id_": "c27672a9-cfa1-4432-9487-f48352c02b25", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f3a19729-24d7-41e2-87f1-aee872bc1164", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "5c43f6719fbc47cfb1d64519497ea94092034f435d0090a8fd37e6719600795e", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n**Test Information:**\n- **Test Type:** Organic Acids Test - Nutritional and Metabolic Profile\n- **Page:** 2 of 11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 286, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a93f0b95-36cf-4e90-a400-7dee8cd344fb": {"__data__": {"id_": "a93f0b95-36cf-4e90-a400-7dee8cd344fb", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d1dd1697-b26c-4f3f-9b34-b255329be451", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "148b182315bff0be8165c25a743539541ec798b264122fd6c36fdf80aaf3cfe4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n**Metabolic Markers in Urine:**\n- **Reference Range:** (mmol/mol creatinine)\n- **Reference Population:** Males Age 13 and Over\n\n| **Metabolite**                     | **Reference Range** | **Patient Value** | **Reference Value** |\n|-------------------------------------|---------------------|-------------------|---------------------|\n| **Oxalate Metabolites**            |                     |                   |                     |\n| Glyceric                            | 0.21 - 4.9          | 2.9               | 2.9                 |\n| Glycolic                            | 18 - 81             | H 87              | 87                  |\n| Oxalic                              | 8.9 - 67            | H 68              | 68                  |\n| **Glycolytic Cycle Metabolites**   |                     |                   |                     |\n| Lactic                              | 0.74 - 19           | H 197             | 197                 |\n| Pyruvic                             | 0.28 - 6.7          | 2.1               | 2.1                 |\n| **Mitochondrial Markers - Krebs Cycle Metabolites** | |                   |                     |\n| Succinic                            | \u2264 5.3               | 0.86              | 0.86                |\n| Fumaric                             | \u2264 0.49              | 0.28              | 0.28                |\n| Malic                               | \u2264 1.1               | 0.00              | 0.00                |\n| 2-Oxoglutaric                       | \u2264 18                | 8.0               | 8.0                 |\n| Aconitic                            | 4.1 - 23            | 12                | 12                  |\n| Citric                              | 2.2 - 260           | 68                | 68                  |\n| **Mitochondrial Markers - Amino Acid Metabolites** | |                   |                     |\n| 3-Methylglutaric                   | 0.02 - 0.38         | 0.36              | 0.36                |\n| 3-Hydroxyglutaric                  | \u2264 4.6               | H 6.0             | 6.0                 |\n| 3-Methylglutaconic                 | 0.38 - 2.0          | 1.5               | * Ratio cannot be calculated because denominator is zero. |\n| **Neurotransmitter Metabolites**   |                     |                   |                     |\n| **Phenylalanine and Tyrosine Metabolites** |           |                   |                     |\n| Homovanillic (HVA)                 | 0.39 - 2.2          | 1.3               | 1.3                 |\n| Vanillylmandelic (VMA)             | 0.53 - 2.2          | 1.7               | 1.7                 |\n| HVA / VMA Ratio                    | 0.32 - 1.4          | 0.80              | 0.80                |\n| Dihydroxyphenylacetic (DOPAC)      | 0.27 - 1.9          | 1.2               | * Ratio cannot be calculated because denominator is zero. |\n| HVA/ DOPAC Ratio                   | 0.17 - 1.6          | 1.1               | 1.1                 |\n| **Tryptophan Metabolites**         |                     |                   |                     |\n| 5-Hydroxyindoleacetic (5-HIAA)    | \u2264 2.9               | 0.89              | 0.89                |\n| Quinolinic                          | 0.52 - 2.4          | 1.4               | 1.4                 |\n| Kynurenic                           | \u2264 1.8               | 1.1               | 1.1                 |\n\n----\n\n**Organic Acids Test - Nutritional and Metabolic Profile**\n**Page 3 of 11**", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3662, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "1dfd9e77-f678-4134-8768-57f17c0c0a27": {"__data__": {"id_": "1dfd9e77-f678-4134-8768-57f17c0c0a27", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "145f0a5a-0a41-4b87-ad16-b21180ee7a64", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "9ed2d793f1589fc95b5073ce9b9cf0809f0b706334b2fc43d478a353b5aee150", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n**Metabolic Markers in Urine**\n*Reference Range (mmol/mol creatinine)*\n*Patient Value*\n*Reference Population - Males Age 13 and Over*\n\n1. **Pyrimidine Metabolites - Folate Metabolism**\n- **Uracil**:\n- Reference Range: \u2264 6.9\n- Patient Value: 1.3\n- **Thymine**:\n- Reference Range: \u2264 0.36\n- Patient Value: 0.10\n\n2. **Ketone and Fatty Acid Oxidation**\n- **3-Hydroxybutyric**:\n- Reference Range: \u2264 1.9\n- Patient Value: H 3.3\n- **Acetoacetic**:\n- Reference Range: \u2264 10\n- Patient Value: 0.87\n- **Ethylmalonic**:\n- Reference Range: 0.13 - 2.7\n- Patient Value: 1.6\n- **Methylsuccinic**:\n- Reference Range: \u2264 2.3\n- Patient Value: 0.79\n- **Adipic**:\n- Reference Range: \u2264 2.9\n- Patient Value: 0.52\n- **Suberic**:\n- Reference Range: \u2264 1.9\n- Patient Value: H 3.2\n- **Sebacic**:\n- Reference Range: \u2264 0.14\n- Patient Value: 0.09\n\n3. **Nutritional Markers**\n- **Vitamin B12**\n- **Methylmalonic**:\n- Reference Range: \u2264 2.3\n- Patient Value: 1.3\n- **Vitamin B6**\n- **Pyridoxic (B6)**:\n- Reference Range: \u2264 26\n- Patient Value: 0.00\n- **Vitamin B5**\n- **Pantothenic (B5)**:\n- Reference Range: \u2264 5.4\n- Patient Value: 3.0\n- **Vitamin B2 (Riboflavin)**\n- **Glutaric**:\n- Reference Range: \u2264 0.43\n- Patient Value: 0.04\n- **Vitamin C**\n- **Ascorbic**:\n- Reference Range: 10 - 200\n- Patient Value: H 330\n- **Vitamin Q10 (CoQ10)**\n- **3-Hydroxy-3-methylglutaric**:\n- Reference Range: \u2264 26\n- Patient Value: 7.7\n- **Glutathione Precursor and Chelating Agent**\n- **N-Acetylcysteine (NAC)**:\n- Reference Range: \u2264 0.13\n- Patient Value: 0.00\n- **Biotin (Vitamin H)**\n- **Methylcitric**:\n- Reference Range: 0.15 - 1.7\n- Patient Value: 0.66\n\n*Note: A high value for certain markers may indicate a deficiency of the corresponding vitamin.*\n\n----\n\n**Organic Acids Test - Nutritional and Metabolic Profile**\n*Page 4 of 11*", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 1959, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "005a9393-58a1-4999-bced-ffca970cb902": {"__data__": {"id_": "005a9393-58a1-4999-bced-ffca970cb902", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "530d90bf-8d62-4be5-a0d1-00059b42ca38", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "ef6de9249833668bd372bac20812243c2de976d0a9d204552c541085ead218b9", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n**Metabolic Markers in Urine:**\n- **Reference Range:** (mmol/mol creatinine)\n- **Reference Population:** Males Age 13 and Over\n\n----\n\n**Indicators of Detoxification:**\n1. **Glutathione**\n- Reference Range: 5.7 - 25\n- Patient Value: 20\n\n2. **2-Hydroxybutyric**\n- Reference Range: \u2264 1.2\n- Patient Value: H 2.2\n\n3. **Orotic**\n- Reference Range: \u2264 0.46\n- Patient Value: 0.28\n\n4. **2-Hydroxyhippuric**\n- Reference Range: \u2264 0.86\n- Patient Value: 0.58\n\n*Notes:*\n- A high value for Glutathione may indicate a deficiency.\n- High values for 2-Hydroxybutyric may indicate methylation defects and/or toxic exposures.\n\n----\n\n**Amino Acid Metabolites:**\n1. **2-Hydroxyisovaleric**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.96\n\n2. **2-Oxoisovaleric**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.21\n\n3. **3-Methyl-2-oxovaleric**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.44\n\n4. **2-Hydroxyisocaproic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.00\n\n5. **2-Oxoisocaproic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.06\n\n6. **2-Oxo-4-methiolbutyric**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.03\n\n7. **Mandelic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.17\n\n8. **Phenyllactic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.07\n\n9. **Phenylpyruvic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.00\n\n10. **Homogentisic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.03\n\n11. **4-Hydroxyphenyllactic**\n- Reference Range: \u2264 2.0\n- Patient Value: 0.26\n\n12. **N-Acetylaspartic**\n- Reference Range: \u2264 38\n- Patient Value: 0.55\n\n13. **Malonic**\n- Reference Range: \u2264 9.9\n- Patient Value: 4.4\n\n14. **4-Hydroxybutyric**\n- Reference Range: \u2264 4.3\n- Patient Value: 2.4\n\n----\n\n**Mineral Metabolism:**\n- **Phosphoric**\n- Reference Range: 1,000 - 4,900\n- Patient Value: 3,466\n\n----\n\n**Organic Acids Test - Nutritional and Metabolic Profile**\n*Page 5 of 11*", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2004, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "23b6c1de-1f91-4995-986a-ff751d206e42": {"__data__": {"id_": "23b6c1de-1f91-4995-986a-ff751d206e42", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "01915641-fd0e-4fdd-9553-904b86b1af64", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "5ef1f93e4314fedbb969fc8be89d8dd027f22285054dbb5241da470a7ae94e91", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n**Indicator of Fluid Intake:**\n- **Creatinine:** 177 mg/dL\n\n*Note: The creatinine test is performed to adjust metabolic marker results for differences in fluid intake. Urinary creatinine has limited diagnostic value due to variability as a result of recent fluid intake. Samples are rejected if creatinine is below 20 mg/dL unless the client requests results knowing of our rejection criteria.*\n\n----\n\n**Explanation of Report Format:**\n- The reference ranges for organic acids were established using samples collected from typical individuals of all ages with no known physiological or psychological disorders.\n- The ranges were determined by calculating the mean and standard deviation (SD) and are defined as + 2SD of the mean.\n- Reference ranges are age and gender specific, consisting of:\n- Male Adult (>13 years)\n- Female Adult (>13 years)\n- Male Child (&#x3C;13 years)\n- Female Child (&#x3C;13 years)\n\n----\n\n**Graphical Representations:**\n1. **Normal Range Graph:**\n- Occurs when the patient's value is within the reference (normal) range, defined as the mean plus or minus two standard deviations.\n\n2. **Elevated Value Graph:**\n- Occurs when the patient's value exceeds the upper limit of normal. In this case, the graphical reference range is \u201cshrunk\u201d to highlight the degree of abnormality. The lower limits of normal are not shown, only the upper limit of normal.\n\n- In both cases, the patient's value is displayed to the left of the graph and is repeated on the graph inside a diamond:\n- If the value is within the normal range, the diamond is outlined in black.\n- If the value is high or low, the diamond is outlined in red.\n\n----\n\n**Examples:**\n- Example of Value Within Reference Range\n- Example of Elevated Value\n\n----\n\n**Document Reference:**\n- Organic Acids Test - Nutritional and Metabolic Profile, Page 6 of 11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2008, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "318628ba-cb78-44e5-806b-c2c4f344d7e7": {"__data__": {"id_": "318628ba-cb78-44e5-806b-c2c4f344d7e7", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d731f7c2-5373-4b52-b464-c3ee74af022f", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "1038db7cd95a7ab0c2ae77f473ee80648f45dc40e0f76ccf5cb10b5b2ae1a7f1", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n**Test Results:**\n- **1.4**\n- **0.89**\n- **0.06**\n- **3.5**\n- **9.8**\n- **1.7**\n- **1.3**\n- **0.80**\n\n**Test Type:**\n- **Organic Acids Test - Nutritional and Metabolic Profile**\n\n**Document Structure:**\n- Page 7 of 11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 390, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ef15fda0-8df7-44a2-82eb-00127fab1094": {"__data__": {"id_": "ef15fda0-8df7-44a2-82eb-00127fab1094", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af630954-e6a2-4866-a665-ed379c83c154", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "a0862c3bfa42732dbb946f8241bfd5fd1c6f0541160b8ef53f3922d2ccc18950", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "# Requisition Information\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n# Interpretation\n\n## High Yeast/Fungal Metabolites\n- **High yeast/fungal metabolites (1-8):** Indicate a yeast/fungal overgrowth in the gastrointestinal (GI) tract.\n- **Recommendations:**\n- Prescription or natural (botanical) anti-fungals.\n- Supplementation of high potency multi-strain probiotics to reduce yeast/fungal levels.\n\n## High Glycolic Acid\n- **High glycolic (20):** Likely due to GI yeast overgrowth (Aspergillus, Penicillium, Candida) or dietary sources containing glycerol/glycerine.\n- **Associated Organisms:**\n- Acetobacter, Acidithiobacillus, Alcanligenes, Corynebacterium, Cryptococcus, Escherichia, Gluconobacter, Kluyveromyces, Leptospirillum, Pichia, Rhodococcus, Rhodotorula, Saccharomyces.\n- **References:**\n- PMID: 11758919; PMID: 26360870; PMID: 14390024.\n\n## High Oxalic Acid\n- **High oxalic (21):** May be associated with:\n- Genetic hyperoxalurias.\n- Autism.\n- Women with vulvar pain.\n- Fibromyalgia.\n- High vitamin C intake (not correlated with kidney stone formation in large studies).\n- **Sources of Oxalates:**\n- Present in most vegetables and fruits.\n- Byproducts of molds (Aspergillus, Penicillium, Candida).\n- **Health Implications:**\n- May cause anemia, skin ulcers, muscle pains, heart abnormalities.\n- Elevated due to anti-freeze (ethylene glycol) poisoning and environmental pollutants.\n- Decomposing vitamin C may form oxalates during transport/storage.\n\n## Genetic Considerations\n- **Elevated oxalate values with glycolic acid:** May indicate genetic hyperoxaluria (type I).\n- **Increased glyceric acid:** May indicate genetic hyperoxaluria (type II).\n- **Normal glyceric/glycolic levels with elevated oxalic acid:** Rules out genetic causes.\n- **Potential new genetic disorder:** Hyperoxaluria type III.\n\n## Management of High Oxalic Acid\n- **Health Risks:** Contributes to kidney stones and may reduce ionized calcium.\n- **Calcium Citrate Supplementation:** May reduce oxalic acid absorption from the GI tract.\n- **Other Supplements:**\n- Vitamin B6, arginine, vitamin E, chondroitin sulfate, taurine, selenium, omega-3 fatty acids, N-acetyl glucosamine may reduce oxalates/toxicity.\n- **Dietary Considerations:**\n- Excessive fats may elevate oxalate if fatty acids are poorly absorbed due to bile salt deficiency.\n\n## Autism and Oxalates\n- **Commonality in Autism:** High levels of oxalates are prevalent.\n- **Causes:** Malabsorption of fat and intestinal Candida overgrowth.\n\n## Steps to Rule Out Genetic Diseases\n1. Follow nutritional steps for one month.\n2. Treat Candida for at least one month if present.\n3. Repeat organic acid test after abstaining from vitamin C supplements for 48 hours.\n4. If markers are still elevated, consider DNA tests for common mutations in oxalate metabolism.\n\n## DNA Testing Options\n- **Mayo Clinic Tests:**\n- Test #89915: AGXT Gene, Full Gene Analysis.\n- Test #83643: Alanine:Glyoxylate Aminotransferase [AGXT] Mutation Analysis [G170R], Blood.\n- **Plasma Oxalate Test:**\n- Available from the Mayo Clinic (Phone: 507.266.5700).\n- Plasma oxalate values > 50 micromol/L are consistent with genetic oxalate diseases.\n\n----\n\n**Document Reference:** Organic Acids Test - Nutritional and Metabolic Profile, Page 8 of 11.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 3367, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "7de2b2bb-0d24-470d-886a-4e75ae941eba": {"__data__": {"id_": "7de2b2bb-0d24-470d-886a-4e75ae941eba", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9f892b52-a782-4048-bbb7-18eccfef09ba", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "2e838eda0fa70c4cdf42baf5150bf09004220ab1a57c342df1ac7775f5aeed0a", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n**Overview of Oxalate and Related Conditions:**\n- Bone is the primary repository for excess oxalate in patients with primary hyperoxaluria.\n- Healthy individuals have negligible bone oxalate levels.\n- Oxalate deposition can lead to increased bone resorption and decreased osteoblast activity.\n\n**Oxalate Deposits:**\n- Can be found in:\n- Kidneys\n- Joints\n- Eyes\n- Muscles\n- Blood vessels\n- Brain\n- Heart\n- May contribute to muscle pain in fibromyalgia.\n- Eye crystal formation can cause severe pain, particularly in individuals with autism who exhibit eye-poking behaviors.\n- High oxalate levels in the GI tract can reduce absorption of essential minerals (calcium, magnesium, zinc, etc.).\n- Oxalate deposits in the breast have been linked to breast cancer.\n\n**Dietary Recommendations:**\n- A low oxalate diet may help reduce body oxalate levels, especially if dysbiosis of GI flora is a major source.\n- Foods high in oxalates include:\n- Spinach\n- Beets\n- Chocolate\n- Soy\n- Peanuts\n- Wheat bran\n- Tea\n- Cashews\n- Pecans\n- Almonds\n- Berries\n\n**Recommendations for Individuals with High Markers:**\n1. Avoid spinach, soy, nuts, and berries for one month.\n2. Treat Candida if present for at least one month.\n3. Repeat the organic acid test after abstaining from vitamin C supplements for 48 hours.\n4. If biochemical markers remain elevated, consider DNA tests for common mutations in oxalate metabolism.\n\n----\n\n**Lactic Acid and Pyruvic Acid:**\n- High levels may result from:\n- Vigorous exercise\n- Bacterial overgrowth\n- Shock\n- Poor perfusion\n- Anemia\n- Mitochondrial dysfunction\n- Values exceeding 300 mmol/mol creatinine suggest a higher likelihood of inborn errors of metabolism; values over 1000 mmol/mol indicate a much higher risk.\n\n**Citric Acid Levels:**\n- Low or low normal citric acid may indicate:\n- Impaired Krebs cycle function\n- Low dietary intake of citrate\n- Potassium deficiency\n- Acidosis\n- Chronic kidney failure\n- Diabetes\n- Hypoparathyroidism\n- Excessive muscle activity\n- Low citric acid levels may increase the risk of oxalate kidney stone formation, especially if oxalic acid is elevated. Supplementation with calcium or magnesium citrate is recommended if oxalic acid is high.\n\n----\n\n**3-Hydroxyglutaric Acid:**\n- Elevated levels are associated with glutaric aciduria type I, a genetic disorder due to glutaryl CoA dehydrogenase deficiency.\n- Symptoms can range from normal to severe neurological issues (e.g., encephalopathy, cerebral palsy).\n- Elevated values may also indicate other conditions (e.g., hepatic carnitine palmitoyltransferase I deficiency).\n- Treatment includes a special diet low in lysine and supplementation with carnitine or acetyl-L-carnitine.\n\n----\n\n**Document Reference:**\n- Organic Acids Test - Nutritional and Metabolic Profile, Page 9 of 11.", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2967, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "ce1e3849-da68-404d-8117-65fec4e3dce9": {"__data__": {"id_": "ce1e3849-da68-404d-8117-65fec4e3dce9", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd343e65-b67f-4b00-bd23-93f1e1bbe789", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "9cda620e4213ee113fb3e7f9fadf73c23c5eb9c47d1602d60e00b36963e476b4", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n----\n\n**Test Results and Interpretations:**\n\n1. **5-Hydroxyindoleacetic Acid (5HIAA)**\n- Levels below the mean may indicate:\n- Lower production and/or decreased metabolism of serotonin.\n- Correlation with symptoms of depression.\n- Possible causes for low production:\n- Decreased intake or absorption of tryptophan (serotonin's precursor).\n- Decreased quantities of cofactors (e.g., tetrahydrobiopterin, vitamin B6).\n- Genetic variations (SNPs or mutations).\n- Note: Low values may be seen in patients on monoamine oxidase (MAO) inhibitors or consuming tyramine-rich foods (e.g., Chianti wine, fermented foods).\n\n2. **3-Hydroxybutyric Acid and Acetoacetic Acid**\n- High levels indicate increased metabolic utilization of fatty acids.\n- Associated with:\n- Diabetes mellitus\n- Fasting\n- Dieting (ketogenic or SCD diet)\n- Illness (e.g., nausea, flu)\n\n3. **Suberic Acid**\n- Slight elevation consistent with:\n- Overnight fasting\n- Increased fat in the diet\n- Recommendation: Supplementation with L-carnitine or acetyl-L-carnitine may be beneficial.\n\n4. **Pyridoxic Acid (Vitamin B6)**\n- Levels below the mean may indicate:\n- Less than optimum health conditions (low intake, malabsorption, dysbiosis).\n- Recommendation: Supplementation with B6 or a multivitamin may be beneficial.\n\n5. **Ascorbic Acid (Vitamin C)**\n- High levels may result from supplementation.\n- Elevated values do not negate the potential benefits of vitamin C.\n\n6. **2-Hydroxybutyric Acid**\n- High levels indicate increased production of sulfur amino acids from homocysteine.\n- Possible reasons for increase:\n1. Increased need for glutathione for detoxification, leading to shunting of homocysteine into cysteine production.\n2. Genetic variants impairing methylation of homocysteine.\n3. Nutritional deficiencies affecting enzyme activities.\n4. Genetic variant in cystathionine beta synthase (CBS) leading to excessive production.\n5. Onset of diabetes mellitus or excessive alcohol use.\n6. Presence of certain genetic diseases (e.g., lactic acidosis, glutaric aciduria type II).\n\n----\n\n**Document Reference:**\n- **Organic Acids Test - Nutritional and Metabolic Profile**\n- **Page:** 10 of 11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 2326, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a4d5eb9f-a9ed-4ae5-8e03-9609edad5e5a": {"__data__": {"id_": "a4d5eb9f-a9ed-4ae5-8e03-9609edad5e5a", "embedding": null, "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef6548f3-2f38-4a44-94e4-2f99ebf16d92", "node_type": "4", "metadata": {"file_name": "1246823_MCCORMICK_OATV4_ENG.pdf", "file_type": "pdf", "file_path": "data\\1246823_MCCORMICK_OATV4_ENG.pdf"}, "hash": "2754ff9d32be124420bd5ada315136de2f74d51677afb83174eb4f3c2ecb35b6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "**Requisition Information:**\n\n- **Requisition #:** 1246823\n- **Practitioner:** Michelle Gaucher\n- **Patient Name:** Geoffrey Mccormick\n- **Date of Collection:** 10/22/2023\n\n**Test Information:**\n\n- **Test Type:** Organic Acids Test - Nutritional and Metabolic Profile\n- **Page:** 11 of 11", "mimetype": "text/plain", "start_char_idx": 1, "end_char_idx": 289, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}}